NYSE:BMY

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. More Details


Snowflake Analysis

Reasonable growth potential average dividend payer.


Similar Companies

Share Price & News

How has Bristol-Myers Squibb's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BMY is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: BMY's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

0.8%

BMY

1.1%

US Pharmaceuticals

1.3%

US Market


1 Year Return

8.7%

BMY

6.2%

US Pharmaceuticals

21.0%

US Market

Return vs Industry: BMY exceeded the US Pharmaceuticals industry which returned 5.6% over the past year.

Return vs Market: BMY underperformed the US Market which returned 20.9% over the past year.


Shareholder returns

BMYIndustryMarket
7 Day0.8%1.1%1.3%
30 Day6.8%7.0%12.1%
90 Day2.3%-0.4%4.8%
1 Year12.0%8.7%8.9%6.2%23.7%21.0%
3 Year9.4%-0.1%25.2%16.0%46.6%36.8%
5 Year4.4%-9.4%37.2%21.3%94.6%73.2%

Long-Term Price Volatility Vs. Market

How volatile is Bristol-Myers Squibb's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bristol-Myers Squibb undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BMY ($62.4) is trading below our estimate of fair value ($136.24)

Significantly Below Fair Value: BMY is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BMY is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: BMY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BMY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BMY is good value based on its PB Ratio (2.8x) compared to the US Pharmaceuticals industry average (3.6x).


Next Steps

Future Growth

How is Bristol-Myers Squibb forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?

88.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BMY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: BMY is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BMY's is expected to become profitable in the next 3 years.

Revenue vs Market: BMY's revenue (4.9% per year) is forecast to grow slower than the US market (10.3% per year).

High Growth Revenue: BMY's revenue (4.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BMY's Return on Equity is forecast to be high in 3 years time (39.8%)


Next Steps

Past Performance

How has Bristol-Myers Squibb performed over the past 5 years?

-3.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BMY is currently unprofitable.

Growing Profit Margin: BMY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BMY is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.

Accelerating Growth: Unable to compare BMY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BMY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.8%).


Return on Equity

High ROE: BMY has a negative Return on Equity (-0.056%), as it is currently unprofitable.


Next Steps

Financial Health

How is Bristol-Myers Squibb's financial position?


Financial Position Analysis

Short Term Liabilities: BMY's short term assets ($34.3B) exceed its short term liabilities ($20.5B).

Long Term Liabilities: BMY's short term assets ($34.3B) do not cover its long term liabilities ($54.8B).


Debt to Equity History and Analysis

Debt Level: BMY's debt to equity ratio (89.5%) is considered high.

Reducing Debt: BMY's debt to equity ratio has increased from 47.7% to 89.5% over the past 5 years.

Debt Coverage: BMY's debt is well covered by operating cash flow (27.6%).

Interest Coverage: BMY is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Next Steps

Dividend

What is Bristol-Myers Squibb current dividend yield, its reliability and sustainability?

2.88%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: BMY's dividend (2.88%) is higher than the bottom 25% of dividend payers in the US market (1.47%).

High Dividend: BMY's dividend (2.88%) is low compared to the top 25% of dividend payers in the US market (4.08%).


Stability and Growth of Payments

Stable Dividend: BMY's dividends per share have been stable in the past 10 years.

Growing Dividend: BMY's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: BMY is paying a dividend but the company is unprofitable.


Future Payout to Shareholders

Future Dividend Coverage: BMY's dividends in 3 years are forecast to be well covered by earnings (25.2% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Giovanni Caforio (55 yo)

5.5yrs

Tenure

US$18,767,253

Compensation

Dr. Giovanni Caforio, M.D. serves as the Chief Executive Officer at Bristol-Myers Squibb Belgium NV/SA. Dr. Caforio has been the Chief Executive Officer of Bristol-Myers Squibb Farmacêutica Portuguesa, SA ...


CEO Compensation Analysis

Compensation vs Market: Giovanni's total compensation ($USD18.77M) is above average for companies of similar size in the US market ($USD10.83M).

Compensation vs Earnings: Giovanni's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Giovanni Caforio
Chairman of the Board & CEO5.5yrsUS$18.77m0.020%
$ 28.1m
David Elkins
Executive VP & CFO1yrUS$5.49m0.0024%
$ 3.5m
Sandra Leung
Executive VP & General Counsel13.67yrsUS$7.52m0.019%
$ 27.7m
Christopher Boerner
Executive VP & Chief Commercialization Officer2.83yrsUS$5.74m0.00093%
$ 1.3m
Rupert Vessey
Executive VP and President of Research & Early Development1yrUS$5.17mno data
Paul von Autenried
Executive VP & Chief Information Officer8.83yrsno data0.0056%
$ 8.0m
Timothy Power
VP & Head of Investor Relationsno datano datano data
Adam Dubow
Senior VP2.83yrsno data0.00071%
$ 1.0m
Ann Powell Judge
Executive VP & Chief Human Resources Officer4.42yrsno data0.0023%
$ 3.2m
Louis Schmukler
Executive VP and President of Global Product Development & Supply3.58yrsUS$4.13m0.0012%
$ 1.7m
Jitendra Tyagi
Head of US Drug Makers - India6.33yrsno datano data
Fouad Namouni
Head of Oncology Development4.33yrsno datano data

4.3yrs

Average Tenure

55yo

Average Age

Experienced Management: BMY's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Giovanni Caforio
Chairman of the Board & CEO5.5yrsUS$18.77m0.020%
$ 28.1m
Michael Bonney
Independent Director1yrUS$48.41k0.00047%
$ 669.6k
Gerald Storch
Independent Director8.83yrsUS$315.00kno data
Vicki Sato
Lead Independent Director3.5yrsUS$393.24kno data
Dinesh Paliwal
Independent Director7.33yrsUS$353.85k0.00098%
$ 1.4m
Matthew Emmens
Independent Director3.67yrsUS$354.81k0.000010%
$ 14.2k
Phyllis Yale
Independent Director1yrUS$78.41kno data
Robert Bertolini
Independent Director3.67yrsUS$332.50k0.00050%
$ 712.4k
Peter Arduini
Independent Director4.58yrsUS$354.81kno data
Theodore Samuels
Independent Director3.67yrsUS$337.50k0.0012%
$ 1.7m
Julia Haller
Independent Director1yrUS$78.41k0.00030%
$ 427.4k
Karen Vousden
Independent Director2.83yrsUS$335.17kno data

3.7yrs

Average Tenure

63yo

Average Age

Experienced Board: BMY's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BMY insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bristol-Myers Squibb Company's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bristol-Myers Squibb Company
  • Ticker: BMY
  • Exchange: NYSE
  • Founded: 1887
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$142.477b
  • Shares outstanding: 2.26b
  • Website: https://www.bms.com

Number of Employees


Location

  • Bristol-Myers Squibb Company
  • 430 East 29th Street
  • 14th Floor
  • New York
  • New York
  • 10016
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BMYNYSE (New York Stock Exchange)YesCommon StockUSUSDJan 1968
BMY *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJan 1968
BRMDB (Deutsche Boerse AG)YesCommon StockDEEURJan 1968
BRMXTRA (XETRA Trading Platform)YesCommon StockDEEURJan 1968
BMYSWX (SIX Swiss Exchange)YesCommon StockCHCHFJan 1968
0R1FLSE (London Stock Exchange)YesCommon StockGBUSDJan 1968
BRMETLX (Eurotlx)YesCommon StockITEURJan 1968
BMYSWBAG (Wiener Boerse AG)YesCommon StockATEURJan 1968
BMYBVL (Bolsa de Valores de Lima)YesCommon StockPEUSDJan 1968
BMYBASE (Buenos Aires Stock Exchange)CEDEAR EACH 3 REP 1ARARSMar 2009
BMYB34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EA REPR 1 COM SHSBRBRLAug 2012

Biography

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therap...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/30 23:13
End of Day Share Price2020/11/30 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.